论文部分内容阅读
过去,异搏停(VR)在临床上主要用于治疗心绞痛及心律失常,而较少用作降血压药。近年国外对VR治疗高血压作了进一步评价.1985年10月,在西柏林举行的一次钙拮抗剂治疗高血压的国际会议,重点讨论了VR治疗高血压。会议对VR治疗高血压评价很高,并认为,在未来十年里,VR将和β-阻滞剂,利尿剂一起成为高血压阶梯治疗方案中的一线药物.
In the past, verapamil (VR) is clinically used mainly for the treatment of angina pectoris and arrhythmia, and less as a hypotensive drug. In recent years, foreign countries have further evaluated the treatment of hypertension in VR. In October 1985, an international conference on the treatment of hypertension with calcium antagonists was held in West Berlin, focusing on VR treatment of hypertension. The meeting evaluated VR-treated hypertension and concluded VR will be the first-line drug in the treatment of hypertension with beta-blockers and diuretics over the next decade.